title: Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.
abstract: The efficacy of Sinemet CR4 (50/200) was compared to standard Sinemet (25/100) in an open label crossover study in 22 patients with Parkinson's disease. All patients experienced end of dose failure and 11 had dyskinesia. Unified Parkinson's disease, Hoehn and Yahr, Schwab and England scores, number of hours on per day, number of hours of dyskinesia per day, daily dose of levodopa, and number of doses per day were monitored at the end of each treatment period and the results compared. The only significant difference in these parameters between the CR4 and standard Sinemet treatment periods in the entire group was a decrease in hours of dyskinesia per day. Two subgroups of CR4 responders were specifically examined. The first subgroup was characterised by a significant increase in on time per day with CR4 therapy. These patients had an older age of onset of Parkinson's disease and a shorter duration of disease and fluctuations than the rest of the patients. The second subgroup was characterised by the presence of dyskinesia with standard Sinemet therapy and a significant decrease in hours of dyskinesia per day with CR4 therapy. Both subgroups required a significantly higher daily dose of levodopa while on CR4. It is concluded that CR4 may be useful in increasing hours on per day in subgroups of Parkinson's disease patients who have less severe fluctuations. It may also be useful in decreasing the number of hours of dyskinesia per day.
authors.affiliation: University of Miami, Department of Neurology, Florida.
authors.forename: S A
authors.initials: SA
authors.lastname: Factor
authors.forename: J R
authors.initials: JR
authors.lastname: Sanchez-Ramos
authors.forename: W J
authors.initials: WJ
authors.lastname: Weiner
authors.forename: A M
authors.initials: AM
authors.lastname: Ingenito
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D001682:Biological Availability; D002230:Carbidopa / Q000009:adverse effects / Q000627:therapeutic use*; D003342:Corpus Striatum / Q000187:drug effects; D003692:Delayed-Action Preparations; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009048:Motor Skills / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D003692:Delayed-Action Preparations; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D002230:Carbidopa